FactSet Increases Dividend by 12%
Get Alerts FDS Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.9%
EPS Growth %: +4.2%
Join SI Premium – FREE
NORWALK, Conn., May 08, 2017 (GLOBE NEWSWIRE) -- FactSet (NYSE: FDS) (NASDAQ: FDS), a global provider of integrated financial information, analytical applications, and industry-leading services, today announced that its Board of Directors approved a 12% increase in the regular quarterly cash dividend from $0.50 per share to $0.56 per share. The $0.06 per share increase marks the twelfth consecutive year the Company has increased dividends, highlighting its continued commitment to returning value to its shareholders. The cash dividend will be paid on June 20, 2017 to holders of record of FactSet’s common stock at the close of business on May 31, 2017.
About FactSet
FactSet (NYSE: FDS) (NASDAQ: FDS) delivers superior analytics, service, content, and technology to help more than 85,000 users see and seize opportunity sooner. We are committed to giving investment professionals the edge to outperform, with fresh perspectives, informed insights, and the industry-leading support of our dedicated specialists. We're proud to have been recognized with multiple awards for our analytical and data-driven solutions and repeatedly ranked as one of Fortune's 100 Best Companies to Work For and a Best Workplace in the United Kingdom and France. Subscribe to our thought leadership blog to get fresh insight delivered daily at insight.factset.com. Learn more at www.factset.com and follow on Twitter: www.twitter.com/factset.
FactSet Investor Relations Contact: Rima Hyder 857.265.7523 [email protected] Media Relations Contact: Amy Bowman 203.810.2144 [email protected]Source: FactSet Research Systems Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jet.AI reviews options for SpaceX equity stake amid reported IPO plans
- TiviMate IPTV Officieel Launches Localized Streaming Packages for Netherlands
- Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Twitter, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share